These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1359 related items for PubMed ID: 16061874

  • 1. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.
    Clin Cancer Res; 2005 Aug 01; 11(15):5566-71. PubMed ID: 16061874
    [Abstract] [Full Text] [Related]

  • 2. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E.
    Cancer Res; 2005 Dec 01; 65(23):11156-63. PubMed ID: 16322266
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G.
    Clin Cancer Res; 2005 Nov 01; 11(21):7891-900. PubMed ID: 16278414
    [Abstract] [Full Text] [Related]

  • 4. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.
    Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J.
    Cancer Res; 2002 Sep 01; 62(17):5041-8. PubMed ID: 12208759
    [Abstract] [Full Text] [Related]

  • 5. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 6. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF.
    Clin Cancer Res; 2004 Jul 01; 10(13):4332-41. PubMed ID: 15240519
    [Abstract] [Full Text] [Related]

  • 7. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, Weber J.
    Clin Cancer Res; 2004 Aug 01; 10(15):5004-13. PubMed ID: 15297401
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW.
    Immunol Lett; 2006 Aug 15; 106(2):126-34. PubMed ID: 16844231
    [Abstract] [Full Text] [Related]

  • 9. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S, Yuan J, Xiang J.
    J Leukoc Biol; 2007 Oct 15; 82(4):829-38. PubMed ID: 17626150
    [Abstract] [Full Text] [Related]

  • 10. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG.
    Vaccine; 2008 Nov 25; 26(50):6433-40. PubMed ID: 18812201
    [Abstract] [Full Text] [Related]

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 25; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 12. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.
    Clin Immunol; 2009 Nov 01; 133(2):184-97. PubMed ID: 19664962
    [Abstract] [Full Text] [Related]

  • 14. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE.
    J Immunol; 1999 Sep 15; 163(6):3239-49. PubMed ID: 10477593
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag.
    Melhem NM, Liu XD, Boczkowski D, Gilboa E, Barratt-Boyes SM.
    Eur J Immunol; 2007 Aug 15; 37(8):2164-73. PubMed ID: 17615585
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 20. MMP11: a novel target antigen for cancer immunotherapy.
    Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L.
    Clin Cancer Res; 2009 Jun 15; 15(12):4104-13. PubMed ID: 19509157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.